Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12304483 | 0.93 | ALDH1A1 (0.53) | SIGMAR1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL19865654 | 0.86 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL15043685 | 0.86 | ALDH1A1 (0.59) | SIGMAR1ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL4958458 | 0.84 | ALDH1A1 (0.56) | SIGMAR1ALDH1A1MEN1KMT2ACHRM1 | |
| SCHEMBL14725157 | 0.81 | SIGMAR1 (0.59) | SIGMAR1HRH3CHRM1NPC1 | |
| SCHEMBL14036400 | 0.81 | SIGMAR1 (0.44) | SIGMAR1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL22871959 | 0.81 | SIGMAR1 (0.59) | SIGMAR1HRH3CHRM1NPC1 | |
| SCHEMBL8290941 | 0.80 | ALDH1A1 (0.56) | SIGMAR1ALDH1A1MEN1KMT2ACHRM1 | |
| SCHEMBL942529 | 0.79 | SIGMAR1 (0.57) | SIGMAR1ALDH1A1POLBHRH3CHRM1 | |
| SCHEMBL22891243 | 0.79 | ALDH1A1 (0.50) | SIGMAR1ALDH1A1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | SIGMAR1 3563/4885ALDH1A1 436/4885MEN1 3475/4885 |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | SIGMAR1 4594/4885ALDH1A1 3295/4885MEN1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.